[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Chagas Disease - Pipeline Insight, 2019

August 2019 | 60 pages | ID: C96FFE30A92EN
DelveInsight

US$ 1,250.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
This report can be delivered to the clients within 24 Hours

"Chagas Disease - Pipeline Insight, 2019" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chagas Disease pipeline landscape is provided which includes the disease overview and Chagas Disease treatment guidelines. The assessment part of the report embraces, in depth Chagas Disease commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chagas Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Chagas Disease Understanding

Chagas Disease is an inflammatory, infectious disease caused by the parasite Trypanosoma cruzi (T. cruzi), which is transmitted to animals and people by insect vectors. Chagas disease is also referred to as American trypanosomiasis. In areas where Chagas disease is common, the main way is through vector borne transmission. The insect vectors are called triatomine bugs. These blood-sucking bugs get infected with T. cruzi by biting an infected animal or person. Once infected, the bugs pass the parasites in their feces. There are two phases of Chagas disease: the acute phase and the chronic phase. Both phases can be symptom free or life threatening. During acute phase, which lasts for the first few weeks or months infection, a person may have no symptoms or mild ones, such as fever, fatigue, body aches, headache, rash, loss of appetite, diarrhea, and vomiting. Because these symptoms are similar to those of other illnesses, most people do not know their illness is from infection with the T. cruzi parasite. While during chronic phase, which can last for decades or even for the entirety of someone’s lifetime, most people have no symptoms. Approximately 20–30 percent of infected people develop cardiac complications and gastrointestinal complications. Chronic disease has two phases: chronic asymptomatic and chronic symptomatic.

Chagas Disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Chagas Disease targeted therapeutics development with respective active and dormant or discontinued projects. Chagas Disease pipeline report covers 17+ companies. Some of the key players include Seren Pharmaceuticals (Fosravuconazole), Sanofi (Fexinidazole), Celera Genomics Group (K 777), etc.

The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university web sites and industry-specific third party sources, etc.

Chagas Disease Analytical Perspective by DelveInsight
  • In-depth Chagas Disease Commercial Assessment of products
This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition –Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing / Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.
  • Chagas Disease Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Scope of the report
  • The Chagas Disease report provides an overview of therapeutic pipeline activity for Chagas Disease across the complete product development cycle including all clinical and non-clinical stages
  • It comprises of detailed profiles of Chagas Disease therapeutic products with key coverage of developmental activities including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product related details
  • Detailed Chagas Disease Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • Therapeutic assessment of the active pipeline products by development stage, product type, route of administration, molecule type, and MOA type
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Chagas Disease
Reasons to Buy
  • Establish a comprehensive understanding of the current pipeline scenario across Chagas Disease to formulate effective R&D strategies
  • Assess challenges and opportunities that influence Chagas Disease R&D
  • Develop strategic initiatives by understanding the focus areas of leading companies.
  • Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage
  • Get in detail information of each product with updated information on each project along with key milestones
  • Devise Chagas Disease in licensing and out licensing strategies by identifying prospective partners with progressing projects for Chagas Disease to enhance and expand business potential and scope
  • Our extensive domain knowledge on therapy areas support the clients in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive or discontinued drugs
1. REPORT INTRODUCTION

2. CHAGAS DISEASE (AMERICAN TRYPANOSOMIASIS)

2.1. Chagas Disease Disease Overview
2.2. Chagas Disease History
2.3. Chagas Disease Symptoms
2.4. Chagas Disease Causes
2.5. Chagas Disease Pathophysiology
2.6. Chagas Disease Diagnosis
  2.6.1. Diagnostic Guidelines

3. CHAGAS DISEASE CURRENT TREATMENT PATTERNS

3.1. Treatment Guidelines

4. CHAGAS DISEASE - DELVEINSIGHT’S ANALYTICAL PERSPECTIVE

4.1. In-depth Commercial Assessment
  4.1.1. Chagas Disease companies collaborations, Licensing, Acquisition –Deal Value Trends
    4.1.1.1. Assessment Summary
  4.1.2. Chagas Disease Collaboration Deals
    4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
    4.1.2.2. Chagas Disease Acquisition Analysis
4.2. Clinical Assessment of Pipeline Drugs
  4.2.1. Assessment by Phase of Development
  4.2.2. Assessment by Product Type (Mono / Combination)
    4.2.2.1. Assessment by Stage and Product Type
  4.2.3. Assessment by Route of Administration
    4.2.3.1. Assessment by Stage and Route of Administration
  4.2.4. Assessment by Molecule Type
    4.2.4.1. Assessment by Stage and Molecule Type
  4.2.5. Assessment by MOA
    4.2.5.1. Assessment by Stage and MOA

5. CHAGAS DISEASE PIPELINE THERAPEUTICS

5.1. Late Stage Products (Phase-III)
  5.1.1. Comparative Analysis
5.2. Mid Stage Products (Phase-II)
  5.2.1. Comparative Analysis
5.3. Early Stage Products (Phase-I)
  5.3.1. Comparative Analysis
5.4. Pre-clinical and Discovery Stage Products
  5.4.1. Comparative Analysis
5.5. Inactive Products

6. CHAGAS DISEASE -PRODUCTS ANALYSIS

6.1. Product Profiles
  6.1.1. Fosravuconazole: Seren Pharmaceuticals
    6.1.1.1. Product Description
      6.1.1.1.1. Product Overview
      6.1.1.1.2. Mechanism of Action
    6.1.1.2. Research and Development
      6.1.1.2.1. Clinical Studies
        6.1.1.2.1.1. Detailed Study Description
        6.1.1.2.1.2. Study Results
        6.1.1.2.1.3. Clinical Trials: Tabular View
    6.1.1.3. Product Development Activities
      6.1.1.3.1. Tabulated Product Summary
        6.1.1.3.1.1. General Description Table
  6.1.2. Fexinidazole: Sanofi
    6.1.2.1. Product Description
      6.1.2.1.1. Product Overview
      6.1.2.1.2. Mechanism of Action
    6.1.2.2. Research and Development
      6.1.2.2.1. Clinical Studies
        6.1.2.2.1.1. Detailed Study Description
        6.1.2.2.1.2. Study Results
        6.1.2.2.1.3. Clinical Trials: Tabular View
    6.1.2.3. Product Development Activities
      6.1.2.3.1. Tabulated Product Summary
        6.1.2.3.1.1. General Description Table
  6.1.3. K 777: Celera Genomics Group
    6.1.3.1. Product Description
      6.1.3.1.1. Product Overview
      6.1.3.1.2. Mechanism of Action
    6.1.3.2. Research and Development
      6.1.3.2.1. Clinical Studies
        6.1.3.2.1.1. Detailed Study Description
        6.1.3.2.1.2. Study Results
        6.1.3.2.1.3. Clinical Trials: Tabular View
    6.1.3.3. Product Development Activities
      6.1.3.3.1. Tabulated Product Summary
        6.1.3.3.1.1. General Description Table
To be continued in the report…………………………

7. RECENT TECHNOLOGIES

8. CHAGAS DISEASE KEY COMPANIES

8.1. Savant HWP
8.2. Uriach
8.3. Max Planck Innovation
8.4. PepTcell
8.5. AstraZeneca
8.6. Celgene Corporation
8.7. Seren Pharmaceuticals
8.8. Sabin Vaccine Institute
8.9. Endo International
8.10. Merck & Co
8.11. Johnson & Johnson
8.12. Astellas Pharma;
8.13. Celera Genomics Group
8.14. Sanofi
8.15. AbbVie
8.16. Collaborations Pharmaceuticals
8.17. Pfizer

9. CHAGAS DISEASE KEY PRODUCTS

9.1. HWP-002
9.2. Albaconazole
9.3. Oleylphosphocholine
9.4. Research programme
9.5. ZD 0870
9.6. Fosravuconazole
9.7. Research programme: Chagas disease vaccines
9.8. Miltefosine
9.9. Research programme: parasitic infection therapeutics
9.10. Research programme: infectious disease therapeutics
9.11. Research programme: tropical disease therapeutics
9.12. K 777
9.13. Fexinidazole
9.14. Research programme: anti-infectives
9.15. Pyronaridine
9.16. Research programme: protozoal infection therapeutics
9.17. Posaconazole
9.18. CGH VL series

10. DORMANT AND DISCONTINUED PRODUCTS

10.1. Dormant Products
  10.1.1. Reasons for being dormant
10.2. Discontinued Products
  10.2.1. Reasons for the discontinuation

11. CHAGAS DISEASE - UNMET NEEDS

12. CHAGAS DISEASE - FUTURE PERSPECTIVES

13. APPENDIX

14. REPORT METHODOLOGY

14.1. Secondary Research
14.2. Expert Panel Validation

LIST OF TABLES

Table 1. Chagas Disease Diagnostic Guidelines
Table 2. Treatment Guidelines
Table 3. Assessment Summary
Table 4. Company-Company Collaborations (Licensing / Partnering) Analysis
Table 5. Chagas Disease Acquisition Analysis
Table 6. Assessment by Phase of Development
Table 7. Assessment by Product Type (Mono / Combination)
Table 8. Assessment by Stage and Product Type
Table 9. Assessment by Route of Administration
Table 10. Assessment by Stage and Route of Administration
Table 11. Assessment by Molecule Type
Table 12. Assessment by Stage and Molecule Type
Table 13. Assessment by MOA
Table 14. Assessment by Stage and MOA
Table 15. Late Stage Products (Phase-III)
Table 16. Mid Stage Products (Phase-II)
Table 17. Early Stage Products (Phase-I)
Table 18. Pre-clinical and Discovery Stage Products
Table 19. Inactive Products
Table 20. Dormant Products
Table 21. Discontinued Products

LIST OF FIGURES

Figure 1. Disease Overview
Figure 2. History
Figure 3. Symptoms
Figure 4. Causes
Figure 5. Pathophysiology
Figure 6. Diagnostic Guidelines
Figure 7. Treatment Guidelines
Figure 8. Chagas Disease companies collaborations, Licensing, Acquisition –Deal Value Trends
Figure 9. Company-Company Collaborations (Licensing / Partnering) Analysis
Figure 10. Chagas Disease Acquisition Analysis
Figure 11. Assessment by Phase of Development
Figure 12. Assessment by Product Type (Mono / Combination)
Figure 13. Assessment by Stage and Product Type
Figure 14. Assessment by Route of Administration
Figure 15. Assessment by Stage and Route of Administration
Figure 16. Assessment by Molecule Type
Figure 17. Assessment by Stage and Molecule Type
Figure 18. Assessment by MOA
Figure 19. Assessment by Stage and MOA
Figure 20. Late Stage Products (Phase-III)
Figure 21. Mid Stage Products (Phase-II)
Figure 22. Early Stage Products (Phase-I)
Figure 23. Pre-clinical and Discovery Stage Products
Figure 24. Inactive Products
Figure 25. Dormant Products
Figure 26. Discontinued Products
Figure 27. Unmet Needs

KEY COMPANIES

Insud Pharma
Savant HWP
Uriach
Max Planck Innovation
PepTcell
AstraZeneca
Bayer
Seren Pharmaceuticals
Sabin Vaccine Institute
Endo International
Merck & Co
Genzyme Corporation
Astellas Pharma;
Celera Genomics Group
Sanofi
AbbVie
Collaborations Pharmaceuticals
Pfizer
Merck & Co.


More Publications